Amporin Pharmaceuticals
Amporin Pharmaceuticals aims to develop a new class of small-molecule drugs that block and eliminate toxic soluble oligomers and pores from within cell membranes.
Amporin Pharmaceuticals has raised €157k across 1 funding round from 1 investor, most recently a round in Jul 2024. Based in Basel, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€157k
€157,000
Funding rounds
1
Investors
1
distinct backers
Active since
2024-07
latest 2024-07
Funding by year
EUR raised per yearAmporin Pharmaceuticals — funding by year — interactive chart.
Data table
| Amporin Pharmaceuticals — funding by year | |
|---|---|
| 2024 | €157k |
Signals
High confidenceRaise-next likelihood17
base rate 30% for Other
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2024-07-25 | Other | €157k | Venture Kick | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData